The long Labor Day weekend is here, which means the summer IPO market has come to an end. Four small issuers began trading this past week, although only two met our tracking criteria. Just two IPOs and one SPAC submitted initial filings. The most notable news...read more
Shuttle Pharmaceuticals, a Phase 2-ready biotech developing drugs to improve radiation therapy, raised $10 million by offering 1.2 million units at $8.13, as expected. Each unit consists of one share of common stock and one warrant, exercisable at...read more
Shuttle Pharmaceuticals, a Phase 2-ready biotech developing drugs to improve radiation therapy, raised the proposed price and lowered the unit offering for its upcoming IPO on Wednesday. The company also added China-based Valuable Capital as an underwriter...read more
Shuttle Pharmaceuticals, a Phase 2-ready biotech developing drugs to improve radiation therapy, lowered the proposed deal size for its upcoming IPO on Friday. The Rockville, MD-based company now plans to raise $10 million by offering 1.7 million units at $6....read more
US IPO Weekly Recap: Summer IPO market ends with more small deals
The long Labor Day weekend is here, which means the summer IPO market has come to an end. Four small issuers began trading this past week, although only two met our tracking criteria. Just two IPOs and one SPAC submitted initial filings. The most notable news...read more
Radiation therapy-focused biotech Shuttle Pharmaceuticals prices IPO at $8.13
Shuttle Pharmaceuticals, a Phase 2-ready biotech developing drugs to improve radiation therapy, raised $10 million by offering 1.2 million units at $8.13, as expected. Each unit consists of one share of common stock and one warrant, exercisable at...read more
Radiation therapy-focused biotech Shuttle Pharmaceuticals increases valuation ahead of proposed $10 million IPO
Shuttle Pharmaceuticals, a Phase 2-ready biotech developing drugs to improve radiation therapy, raised the proposed price and lowered the unit offering for its upcoming IPO on Wednesday. The company also added China-based Valuable Capital as an underwriter...read more
Radiation therapy-focused biotech Shuttle Pharmaceuticals lowers deal size, adds warrants ahead of $10 million IPO
Shuttle Pharmaceuticals, a Phase 2-ready biotech developing drugs to improve radiation therapy, lowered the proposed deal size for its upcoming IPO on Friday. The Rockville, MD-based company now plans to raise $10 million by offering 1.7 million units at $6....read more